Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

Figure 1

Treatment design schema. Schema is for subjects enrolled on NCT00752206, including the crossover design that was implemented in 2012.